` ALT (Altimmune Inc) vs S&P 500 Comparison - Alpha Spread

ALT
vs
S&P 500

Over the past 12 months, ALT has underperformed S&P 500, delivering a return of -29% compared to the S&P 500's 8% growth.

Stocks Performance
ALT vs S&P 500

Loading

Performance Gap
ALT vs S&P 500

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
ALT vs S&P 500

Loading
ALT
S&P 500
Add Stock

Competitors Performance
Altimmune Inc vs Peers

S&P 500
ALT
ABBV
AMGN
GILD
VRTX
Add Stock

Altimmune Inc
Glance View

Market Cap
374.1m USD
Industry
Biotechnology

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 47 full-time employees. The company went IPO on 2005-10-06. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The company is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The firm has initiated a Phase II clinical trial of HepTcell and are in Phase II and Phase I clinical development with pemvidutide for multiple indications. The company is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany and Spain, and conducting Its pemvidutide Phase I clinical trial in Australia. Its wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

ALT Intrinsic Value
HIDDEN
Show
Back to Top